Campo Santo Therapeutics

Campo Santo Therapeutics is a San Francisco-based biotech company pioneering a new class of ibogaine-derived compounds designed to treat addiction and neurological disorders. The company's core technology leverages the therapeutic potential of ibogaine, a naturally occurring alkaloid with proven efficacy in addiction treatment, while engineering out its dangerous cardiac side effects through novel chemical modifications. Their proprietary platform enables the development of safer, more efficacious medicines that harness ibogaine's unique neuroplasticity-enhancing properties without the toxicity concerns that have limited clinical adoption of the parent compound.

Campo Santo has raised $8 million in seed funding and is advancing a focused pipeline targeting opioid use disorder and traumatic brain injury, two major unmet medical needs in neurology and psychiatry. The company's approach positions it at the forefront of the emerging psychedelic therapeutics space, where several organizations are exploring classical psychedelics for brain repair and behavioral change. By eliminating the cardiac risk profile that has historically prevented ibogaine from broader clinical use, Campo Santo is uniquely positioned to unlock the therapeutic potential of this powerful molecule for mainstream medical practice.

The company represents a critical bridge between traditional drug discovery and the emerging psychedelic renaissance in neuromedicine, demonstrating how rigorous medicinal chemistry can make traditionally challenging compounds viable pharmaceuticals. Their work addresses the opioid crisis and traumatic brain injury epidemic with a novel mechanism that could reshape how we approach addiction treatment and neurological repair. As the field matures and regulatory pathways for psychedelic therapeutics become clearer, Campo Santo's engineering approach to mitigating safety liabilities will likely influence how the entire sector develops next-generation compounds with improved risk-benefit profiles.